Diabetes patients who were implanted with a second-generation everolimus-eluting stent showed lower stent thrombosis rates and all-cause mortality compared with those who had first-generation sirolimus-eluting and paclitaxel-eluting stents, a study indicated. The results appear in the Journal of the American College of Cardiology: Cardiovascular Interventions.